A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid Tumors

Summary

In this study, the safety, tolerability and preliminary effectiveness of GNC-035 in participants with locally advanced or metastatic solid tumors will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum administered dose (MAD) for MTD is not reached of GNC-035.

Timeline

Start

2021-09-15

Primary completion

2023-06

Completion

2023-06

Outcome

Outcome not reported

Stopped (Enrollment): “leading entity of the clinical trial was replaced, and no patients were enrolled.”

Drugs

Indications